Thymic Stromal Lymphopoietin (TSLP) in Vitiligo

Study of the Cutaneous Expression of Thymic Stromal Lymphopoietin (TSLP) in a Sample of Vitiligo Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03367273

Enrollment

Registered

2017-12-08

Start date

2017-01-31

Completion date

2017-07-31

Last updated

2017-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

study & verify the hypothesis of the involvement of TSLP in the pathogenesis of vitiligo in comparison to their levels in the healthy control persons.

Interventions

OTHERskin biopsy

Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* • Patients with generalized non-segmental vitiligo. * Both sexes. * Age \< 18 years old age. * New cases or cases not receiving any medication for at least 3 months ago.

Exclusion criteria

* • Age: Patients \< 18 years. * Segmental or universal vitiligo. * Pregnant and lactating females. Autoimmune diseases

Design outcomes

Primary

Measure	Time frame
Expression levels of TSLP in patients of Vitiligo.	7 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026